Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

From €0.48 to €4.80: Capital B Reverse Split Chases Institutional Money

A stock trading near €0.48 on Euronext Growth Paris...

Tether Gold Recognition: Abu Dhabi Backs $2.5B Tokenized Commodity

Abu Dhabi just handed Tether Gold a formal regulatory...

Ryanair Holdings plc Stock Drops $2.13 From Highs as MACD Turns Bearish

Ryanair Holdings plc stock faces a precarious moment. RYAAY...

Alibaba Group Holding Limited Stock Surged 5.4% on AI — Now Faces Key Test

Alibaba Group Holding Limited stock trades at a critical...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.